文献速递细菌感染、耐药与抗菌药物

以黏菌素-利福平为基础的三联抗菌药物联合方案对碳青霉烯耐药铜绿假单胞菌的协同效应:时间-杀菌试验

Synergistic effects of colistin-rifampin-based triple antimicrobial combination therapy against Carbapenem-resistant Pseudomonas aeruginosa: a time-kill assay.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

研究使用2016至2018年亚洲细菌库保存的12株碳青霉烯耐药铜绿假单胞菌血液分离株,通过时间-杀菌试验评估含黏菌素和/或利福平联合亚胺培南、美罗培南或头孢他啶-阿维巴坦的双联或三联方案的体外协同作用。结果显示,所有三联方案在1×和0.5×最低抑菌浓度下均达到0 log cfu/mL,且协同率和杀菌活性均高于黏菌素-利福平双联方案。

要点

  • 12株碳青霉烯耐药铜绿假单胞菌中9株产金属β-内酰胺酶(6株IMP-6、2株VIM-2、1株NDM-1)。
  • 黏菌素-利福平双联方案在24小时孵育后中位活菌数最低,1×MIC为2.25 log cfu/mL,0.5×MIC为3.71 log cfu/mL。
  • 所有三联方案在1×MIC和0.5×MIC下均达到0 log cfu/mL,协同率和杀菌活性均高于黏菌素-利福平双联方案。

核心结论

  • 以黏菌素-利福平为基础的三联抗菌药物联合方案在清除碳青霉烯耐药铜绿假单胞菌方面,较双联抗菌药物方案表现出更强的协同作用和杀菌活性。

研究设计与样本

  • 体外时间-杀菌试验,使用2016年至2018年亚洲细菌库保存的12株碳青霉烯耐药铜绿假单胞菌血液分离株,所有菌株经多位点测序和碳青霉烯酶多重PCR检测。
  • 评估含黏菌素和/或利福平联合亚胺培南、美罗培南或头孢他啶-阿维巴坦的双联或三联方案,在1×和0.5×最低抑菌浓度下进行时间-杀菌试验。

主要发现

  • 12株碳青霉烯耐药铜绿假单胞菌中9株产金属β-内酰胺酶(6株IMP-6、2株VIM-2、1株NDM-1)。
  • 时间-杀菌试验中,黏菌素-利福平双联方案在24小时孵育后中位活菌数最低,1×MIC为2.25 log cfu/mL,0.5×MIC为3.71 log cfu/mL。
  • 所有三联方案在1×MIC和0.5×MIC下均达到0 log cfu/mL。
  • 与黏菌素-利福平双联方案相比(协同率:1×MIC为25%,0.5×MIC为42%;杀菌活性:1×MIC为50%,0.5×MIC为42%),所有三联方案在1×MIC下协同率为50%-75%、杀菌活性为75%-83%,在0.5×MIC下协同率和杀菌活性均为58%-75%。

关键数值与推荐

  • 以黏菌素-利福平为基础的三联抗菌药物联合方案在1×MIC和0.5×MIC下协同率为50%-75%和58%-75%,杀菌活性为75%-83%和58%-75%。
  • 黏菌素-利福平双联方案在1×MIC和0.5×MIC下协同率为25%和42%,杀菌活性为50%和42%。

临床怎么用

  • 原文结论指出,以黏菌素-利福平为基础的三联抗菌药物联合方案在清除碳青霉烯耐药铜绿假单胞菌方面较双联方案表现出更强的协同作用和杀菌活性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Our research aimed to investigate the potential of in vitro triple antimicrobial synergism against carbapenem-resistant Pseudomonas aeruginosa (CRPA) as a strategy to overcome antimicrobial resistance. METHODS: We used 12 CRPA blood isolates stocked in the Asian Bacterial Bank between 2016 and 2018. All isolates were tested by multi-locus sequencing and carbapenemase multiplex PCR. To assess the antimicrobial interactions, we performed time-kill assays using double or triple combination regimens. These regimens included CST and/or rifampin combined with IPM, MEM, or CZA. The assay was conducted at 1× and 0.5× MICs. RESULTS: Among the 12 CRPA isolates, nine produced metallo-beta-lactamases (6 IMP-6, 2 VIM-2 and 1 NDM-1). In the time-kill assay, the median viable bacterial count for CST-rifampin was the lowest among double combinations after 24 h incubation (2.25 log cfu/mL at 1× MIC and 3.71 log cfu/mL at 0.5× MIC). In contrast, all triple combinations achieved 0 log cfu/mL at both 1× MIC and 0.5× MIC. Compared with CST-rifampin (synergism: 25% at 1× MIC, 42% at 0.5× MIC; bactericidal: 50% at 1× MIC, 42% at 0.5× MIC), all triple combinations showed greater synergism and bactericidal activity at both 1× MIC (50%-75% for synergism, 75%-83% for bactericidal activity) and 0.5× MIC (58%-75% for both). CONCLUSIONS: Our findings suggest that CST-rifampin-based triple antimicrobial combinations exhibit greater synergy and bactericidal activity in eradicating CRPA compared with double antimicrobial combinations.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Kim SH, Kim HM, Chung DR, et al. Synergistic effects of colistin-rifampin-based triple antimicrobial combination therapy against Carbapenem-resistant Pseudomonas aeruginosa: a time-kill assay. J Antimicrob Chemother. 2025. PMID: 39737887. doi:10.1093/jac/dkae466

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。